Mark H. Mirochnick, MD
Professor
Boston University School of Medicine
Dept of Pediatrics
Neonatology

MD, University of Vermont College of Medicine



Mark Mirochnick, MD is Professor of Pediatrics and Chief of the Division of Neonatology at Boston University School of Medicine/Boston Medical Center. His main research involves investigating the effects of antiretrovirals in infants, children and pregnant women. He has served as protocol chair, investigator and/or protocol pharmacologist for HIV protocols on more than two continents. He currently serves as co-chair of the US Perinatal HIV Guidelines Committee and is a member of numerous Committees for HIV research including the WHO Pediatric Antiretroviral Working Group.

Section Director
Boston University School of Medicine
Pediatrics
Neonatology

Active Staff Privileges
Boston Medical Center
Pediatrics




A 48 Week, Phase II, Open-Label, Multi-Cohort, Multicenter Study to Evaluate the Safety , Tolerability, Pharmacokinetics, and Antiviral Activity of GW433908/Ritonavir QD when Administered to HIV-1 Infected, Antiretrovitral Naive and Experienced, Pediatric
07/01/2002 - 06/30/2006 (PI)
GlaxoSmithKline, Inc.

Open-Label Multicenter Multiple Dose Phase III Study of the Population Pharmacokinetics of IV Synecid 7.5 mg/kg q8h in &5 Pediatric Patients
11/01/2001 - 10/31/2003 (PI)
Aventis Pharmaceuticals Inc

Investigation of CD11b Expression in Neonates Using New Laser Scanning Cytometer Technology
10/19/1999 - 09/30/2000 (PI)
CompuCyte Corporation


LDR09 - P1026s: Pharmacokinetic Properties of Antiretroviral and Related Drugs During Pregnancy...
07/01/2018 - 06/30/2021 (PI)
Johns Hopkins University Gilead Sciences

IMPAACT 2007 - Phase I Safety and Pharmacokeneticks of Marviorc in HIV 1 Exposed Infants at Risk …
07/01/2016 - 12/31/2019 (PI)
Johns Hopkins University Phivco UK II Ltd.

LDR 01: LOC-IMPAACT Leadership Group: Mirochnick
01/01/2014 - 11/30/2019 (PI)
Johns Hopkins University NIH-NIAID
5UM1AI068632-13

Plugging Hair ARV Levels as Adherence Biomarkers into HIV Prevention Trials
12/01/2012 - 11/30/2016 (PI)
Univ of California, San Francisco NIH-NIAID

IMPAACT: HIV Treatment SC VC
06/01/2012 - 12/31/2014 (PI)
Johns Hopkins University NIH-NIAID

IMPAACT: Network Executive Committee (NEC)
06/01/2012 - 12/31/2013 (PI)
Johns Hopkins University NIH-NIAID

IMPAACT Group Leadership
07/01/2006 - 06/30/2013 (PI)
Social & Scientific Systems Inc. NIH-NIAID

Pharmacokinetic Study of Praziquantel During Pregnancy
04/01/2009 - 03/31/2013 (PI)
Rhode Island Hospital NIH-NIAID

IMPAACT Leadership: International Maternal Pediatric Adolescent AIDS Clinical Trials Group (IMPAACT)
06/01/2011 - 05/31/2012 (PI)
Social & Scientific Systems Inc. NIH-NIAID

Congenital Transmission of Lineages I and II of Trypanasoma Cruzi
09/08/2011 - 02/29/2012 (PI)
Tulane Univ Health Sciences Center NIH-NIA

Showing 10 of 15 results. Show All Results


Yr Title Project-Sub Proj Pubs
2008 Safety Pharmacokinetics &Efficacy of Artemether &Lumefantrine in Pregnant Women 1R34AI076610-01
2007 ANTIRETROVIRAL DRUGS DURING PREGNANCY, SUBSTUDY OF PACTG P1025 2M01RR000533-39-8139 439
2007 PERINATAL CORE PROTOCOL FOR HIV INFECTED WOMEN (PACTG P1025, VERSION 20) 2M01RR000533-39-8144 439
2007 PHARMACOKINETICS OF ANTIRETROVIRAL DRUGS IN PREGNANT HIV INFECTED WOMEN 2M01RR000533-39-8160 439
2006 ANTIRETROVIRAL DRUGS DURING PREGNANCY, HIV INFECTED WOMEN (SUB OF PACTG P1025) 5M01RR000533-38-5584 439
2006 PERINATAL CORE PROTOCOL FOR HIV INFECTED WOMEN (PACTG P1025, VERSION 20) 5M01RR000533-38-5591 439
2006 Antiretroviral Pharmacology/Lactating Mother/Infants 5R21HD051470-02 1
2005 Antiretroviral Pharmacology/Lactating Mother/Infants 1R21HD051470-01 1
2005 ANTIRETROVIRAL DRUGS DURING PREGNANCY IN HIV POSITIVE FEMALES 5M01RR000533-37-5424 439
2005 PERINATAL CORE PROTOCOL IN HIV INFECTED WOMEN (PACTG P1025, VERSION 20) 5M01RR000533-37-444 439
Showing 10 of 22 results. Show All Results
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.

  1. Schalkwijk S, Ter Heine R, Colbers A, Capparelli E, Best BM, Cressey TR, Greupink R, Russel FGM, Moltó J, Mirochnick M, Karlsson MO, Burger DM. Evaluating darunavir/ritonavir dosing regimens for HIV-positive pregnant women using semi-mechanistic pharmacokinetic modelling. J Antimicrob Chemother. 2019 Jan 30. PMID: 30715324.
     
  2. Kreitchmann R, Schalkwijk S, Best B, Wang J, Colbers A, Stek A, Shapiro D, Cressey T, Mirochnick M, Burger D. Efavirenz pharmacokinetics during pregnancy and infant washout. Antivir Ther. 2018 Dec 10. PMID: 30530925.
     
  3. Momper JD, Best BM, Wang J, Capparelli EV, Stek A, Barr E, Badell ML, Acosta EP, Purswani M, Smith E, Chakhtoura N, Park K, Burchett S, Shapiro DE, Mirochnick M. Elvitegravir/cobicistat pharmacokinetics in pregnant and postpartum women with HIV. AIDS. 2018 Nov 13; 32(17):2507-2516. PMID: 30134297.
     
  4. Schalkwijk S, Ter Heine R, Colbers AC, Huitema ADR, Denti P, Dooley KE, Capparelli E, Best BM, Cressey TR, Greupink R, Russel FGM, Mirochnick M, Burger DM. A Mechanism-Based Population Pharmacokinetic Analysis Assessing the Feasibility of Efavirenz Dose Reduction to 400 mg in Pregnant Women. Clin Pharmacokinet. 2018 Nov; 57(11):1421-1433. PMID: 29520730.
     
  5. Eke AC, McCormack SA, Best BM, Stek AM, Wang J, Kreitchmann R, Shapiro D, Smith E, Mofenson LM, Capparelli EV, Mirochnick M. Pharmacokinetics of Increased Nelfinavir Plasma Concentrations in Women During Pregnancy and Postpartum. J Clin Pharmacol. 2019 Mar; 59(3):386-393. PMID: 30358179.
     
  6. Adachi K, Xu J, Ank B, Watts DH, Camarca M, Mofenson LM, Pilotto JH, Joao E, Gray G, Theron G, Santos B, Fonseca R, Kreitchmann R, Pinto J, Mussi-Pinhata MM, Machado DM, Ceriotto M, Morgado MG, Bryson YJ, Veloso VG, Grinsztejn B, Mirochnick M, Moye J, Nielsen-Saines K. Congenital Cytomegalovirus and HIV Perinatal Transmission. Pediatr Infect Dis J. 2018 Oct; 37(10):1016-1021. PMID: 30216294.
     
  7. Schreiner CN, Ahlfors CE, Wong RJ, Stevenson DK, Clarke DF, Mirochnick M. In Vitro Study on the Effect of Maraviroc or Dolutegravir on Bilirubin to Albumin Binding. Pediatr Infect Dis J. 2018 Sep; 37(9):908-909.View Related Profiles. PMID: 29561509.
     
  8. Eke AC, Chakhtoura N, Kashuba A, Best BM, Sykes C, Wang J, Stek AM, Smith E, Calabrese S, Capparelli EV, Mirochnick M. Rilpivirine Plasma and Cervicovaginal Concentrations in Women During Pregnancy and Postpartum. J Acquir Immune Defic Syndr. 2018 Jul 01; 78(3):308-313. PMID: 29528944.
     
  9. Mulligan N, Best BM, Wang J, Capparelli EV, Stek A, Barr E, Buschur SL, Acosta EP, Smith E, Chakhtoura N, Burchett S, Mirochnick M. Dolutegravir pharmacokinetics in pregnant and postpartum women living with HIV. AIDS. 2018 Mar 27; 32(6):729-737. PMID: 29369162.
     
  10. Adachi K, Xu J, Ank B, Watts DH, Camarca M, Mofenson LM, Pilotto JH, Joao E, Gray G, Theron G, Santos B, Fonseca R, Kreitchmann R, Pinto J, Mussi-Pinhata MM, Machado DM, Ceriotto M, Morgado MG, Bryson YJ, Veloso VG, Grinsztejn B, Mirochnick M, Moye J, Nielsen-Saines K. Congenital CMV and HIV Perinatal Transmission. Pediatr Infect Dis J. 2018 Mar 09. PMID: 29528912.
     
Showing 10 of 109 results. Show More

This graph shows the total number of publications by year, by first, middle/unknown, or last author.

Bar chart showing 109 publications over 31 distinct years, with a maximum of 11 publications in 2018

YearPublications
19863
19881
19901
19911
19933
19943
19951
19962
19971
19983
19997
20004
20013
20023
20033
20041
20054
20063
20072
20086
20093
20103
20119
20125
20134
20147
20155
20162
20174
201811
20191
In addition to these self-described keywords below, a list of MeSH based concepts is available here.

Neonatology
Contact for Mentoring:

771 Albany St
Boston MA 02118
Google Map


Mirochnick's Networks
Click the "See All" links for more information and interactive visualizations
Concepts
_
Co-Authors
_
Similar People
_
Same Department